Press Release

IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders

spotthedot2022-06-29T11:39:18+00:00June 29th, 2022|

IACTA Pharmaceuticals to Present at Jefferies Healthcare Conference

spotthedot2022-06-02T20:11:13+00:00June 1st, 2022|

IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology

spotthedot2022-03-17T02:18:53+00:00December 17th, 2021|

IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury

spotthedot2022-03-17T02:19:31+00:00October 28th, 2021|

IACTA Pharmaceuticals Appoints Yogesh Bahl as Chief Financial Officer and Eric Carter, M.D., Ph.D., as Chief Medical Officer

spotthedot2022-03-17T02:19:53+00:00July 27th, 2021|

IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain

spotthedot2022-03-17T02:20:27+00:00January 7th, 2021|

New licensing agreement accelerates the development of IACTA Pharmaceuticals’ novel dry eye disease and allergic conjunctivitis treatments on China and Southeast Asia

spotthedot2022-03-17T02:21:34+00:00July 28th, 2020|

Update on the in-licensing and research and development of ophthalmology products

spotthedot2022-03-17T02:21:49+00:00May 8th, 2020|